Jianmin has more than 30 years of drug development experience, including 21 years in drug discovery and development at Boehringer Ingelheim, overseeing all preclinical drug development programs of the company. Jianmin is an expert in preclinical and clinical features of drug absorption, distribution, metabolism and excretion. His in-depth understanding of pharmacology provides important guidance on development programs, including regulatory aspects related to toxicology. Jianmin holds a PhD in pharmacology from Dalhousie University.

• 

  Executive Vice-President, ADME/PK & Pharmacology in Inversago Pharma

  Transformative therapies for the treatment of metabolic and fibrotic diseases